



Article History

Submitted: 21-05-2024

Revised: 11-06-2024

Accepted: 15-06-2024

Corresponding Author:

Abdul Samad

Buzdarabdulsamad@gmail.com

Unravelling the Mysteries of Zika Virus: A Comprehensive Overview

**Rabbya Rayan Shah¹, Ambreen Talib², Tehreem Ferdos³, Huda Akmal⁴,
Hamna Yamin⁵, Maryam Zahra⁶, Ayesha Nadeem⁷, Bushra Anwar⁸, Abia
Muazzam⁹, Fatima hameed¹⁰, Abdul Samad^{11*}**

^{1, 2,3,4,5,7,10} Department of Pathobiology and Biomedical Sciences, Muhammad
Nawaz Shareef University of Agriculture, 25000, Multan, Pakistan

⁶Department of Veterinary and Animal Sciences Muhammad Nawaz Shareef
University of Agriculture, 25000, Multan, Pakistan

⁸National University of medicine sciences (NUMS), Rawalpindi, Pakistan

⁹Department of Biochemistry and Biotechnology, Muhammad Nawaz Shareef
University of Agriculture, 25000, Multan, Pakistan

¹¹Department of Animal Science, Gyeongsang National University 501, Jinju-
daero, South Korea

¹rabbayarayanshah@gmail.com, ²ambreentalib212@gmail.com

³tehreemfirdous203@gmail.com, ⁴bhuttahudaakmal09@gmail.com,

⁵hamnayamin8@gmail.com, ⁶maryamzahra309@gmail.com,

⁷ayeshanadeem5200@gmail.com, ⁸bushraanwar058@gmail.com,

⁹abiamuazzam@gmail.com, ¹⁰fatimahameed838@gmail.com,

¹¹Buzdarabdulsamad@gmail.com



Abstract

The Zika virus (ZIKV), which emerged in an epidemic state in 2016, poses a serious risk to the health of society. It could appear as a serious condition with signs such as migraine and a high body temperature or it can appear benign. *Aedes* species of mosquitoes (family Flaviviridae, genus *Flavivirus*) are responsible for the transmission of ZIKA virus to humans. Even though over half of civilization lives in areas where *Aedes aegypti* is common, there is still concern about the possibility of its revival. Global accounts of Zika virus infections have recently been made, especially from America; French Polynesia and other Pacific Island nations; and south-East Asia. ZIKV was first discovered in 1947 in the Ugandan Zika Forest, in a rhesus monkey. Since the beginning of discoveries in Africa and Asia in 2007, the virus expanded around every continent. A serious infection frequently results in a short-term febrile illness, but recent evidence reveals that it may also be linked to additional important adverse effects like microcephaly in infants and Guillain-Barré syndrome. This review provides knowledge about the pathophysiology of ZIKV, reveals essential cellular processes that develop during infections, and recalls the origins of the virus from when it was first discovered to its current worldwide propagation.

Keywords

Zika virus, Epidemic, *Aedes* species, infection, public health

Introduction

Zika virus is an arbovirus (virus carried by arthropods). It is a microscopic encapsulated positive-stranded RNA virus that is a member of the Flaviviridae family, which is also linked to the viruses that cause dengue, yellow fever, and West Nile [1]. It originally emerged in 1947 in the rhesus monkey inhabiting the Zika forest near Kampala, Uganda [2]. The two main origins of the single-stranded RNA Zika virus are Asian and African [3]. It is believed that the Zika virus has mainly survived in Africa through a cycle of infection between mosquitoes and non-human hosts, including apes, monkeys, and humans serving as rare accidental hosts [4].

However, outside of Africa, humans are most likely the primary host. There are currently just two Zika virus genome sequences from the present pandemic in South America. A Suriname Zika virus's phylogenetic research reveals that it is of the Asian genotype [5]. As they share more than 99.7% and 99.9% of identical nucleotide and amino acid identities, respectively, the strain that was propagating in French Polynesia in 2013 is most closely linked to that strain. Analysis of the envelope genomes from Brazilian patients supports this conclusion [6]. It's possible that a mutation in the Asian lineage caused the virus to adapt to a human host rather than a non-human animal [7].



The Zika virus can spread quickly through skin immune cells and can enter cells through a wide variety of receptors [8]. To learn more about the connection to neurological disorders, research into the virus's capacity for replication in neuronal cells is necessary [9]. In February 2016, WHO named Zika as the virus that causes illness, a global public health emergency [10]. Although there has been a decrease in ZIKV transmission since 2017, the virus is still present and has the potential to create major outbreaks in specific areas [11]. Although there has been a decrease in ZIKV transmission since 2017. The virus is still present and has the potential to create major outbreaks in specific areas [12]. Therefore, we go over the most recent research on the epidemiology, spread, immunogenicity, host variables, clinical characteristics, and possible therapies for Zika in this review.

Epidemiology

Anxiety emerged as the Zika virus (ZIKV) spread across the world, especially across countries in Latin America and the Caribbean. During the 2016 outbreak, there were between 440,000 and 1,300,000 cases in Brazil [13]. In addition, ZIKV spread rapidly, with 60 countries and territories reporting active ZIKV exposure as of July 21, 2016. In light of the aforementioned, on February 1, 2016, the World Health Organization (WHO) declared ZIKV to be “a worldwide health crisis of global frustration” [14] and emphasized the necessity of taking immediate action to reduce its infection, particularly in women who are pregnant and of childbearing age [15].

In 1947, a rhesus monkey in the Zika forest in Kampala, was the first carrier of this virus [16]. After five years, the virus was discovered to be wildly spreading over Africa for the first time [17]. Then, in the 1980s, a distinct strain of the virus—not the same as the one in Africa—migrated to Asia [18].

Furthermore, the Asian strain has led to localized outbreaks outside of Asia, with the result that French Polynesia experienced larger outbreaks in 2007, 2013, and 2014 [19]. In May 2015, the greatest Zika virus outbreak in history happened in northeastern Brazil and reached pandemic proportions. An estimated 1.62 million people worldwide are thought to have contracted ZIKV, with cases peaking along the Pacific, American, and West African coast regions [20].



More than 70 countries worldwide have reported instances of the virus. Based on their respective geographic origins, ZIKV has been phylogenetically split into two primary lineages: the African and the Asian. Viral spread in East and West Africa is divided in branch of Africa [21]. **(Figure 1)**



Figure 1: ZIKV infected areas according to time

1. Genomic Organization of ZIKA VIRUS:

ZIKV are related in context of size and genetic profiles [22]. The genome of ZIKV is roughly 10.7 kb long. It contains only one polyprotein, three structural (S) proteins, a pre-membrane protein (PrM), a capsid (C) protein, and envelope protein (E). It also contains seven non-structural proteins and Ns1-Ns5 that are important for ZIKV as they make up two main parts of its genome [23]. Untranslated regions 5' and 3' around the ZIKV genome. In case of vector borne transmission, the virus is closer to YFV and DENVs [24].

2. Mode of transmission:

The primary method of Zika virus transmission to humans is by the bite of an infected *Aedes aegypti* mosquito, which typically bites during the day time and grow in fresh standing water (both indoors and outdoors) [25]. ZIKV can also be carried by *Aedes albopictus* and other *Aedes* mosquito species, such as *A. africanus*, *A. luteocephalus*, *A. furcifer*, and *A. taylori* [26].



2.1. Vector borne transmission:

Aedes aegypti, *Ae. vexans*, *Ae. notoscriptus*, *Ae. vittatus*, and *Culex quinquefasciatus* are carriers for the transmission of ZIKV Infection [27]. *Anopheles gambiae*, *Cx pipiens* and *A. stephensi* are Considered to be probable vectors [28]. However, in America Culicidae family compete with *Aedes* species as a potential vector to transmit ZIKV. When *Aedes* mosquito bites an infected rhesus monkey, it act as a carrier for ZIKV. When this mosquito bites a healthy person, it transmits zika virus in humans and cause infection as shown in (Figure 2)

2.2. Non-Vector borne transmission:

2.2.1. Transmission through urine:

ZIKV is actively found in human urine and cause viremia [29]. When *A. aegypti* and *A. albopictus* were discovered breeding in urine-contaminated or ZIKV-infected environments, they become susceptible to ZIKV infections [29]. These two kinds of mosquitoes can transmit the Zika virus to adult female mosquitoes through transmitting infection to larvae and pupae of mosquitoes in contaminated urine environments [29]. Urine contained infectious ZIKV particles, according to a body of evidence [30]. About five ZIKV infectious strains were found when human urine samples were cultured, indicating that the infectious Zika virus was released by the viruria of ZIKV-infected individuals [30]. Furthermore, two other investigations found that one patient's urine contained Zika virus titer of roughly 10 pfu/ml, while three more patients' urine samples contained 12–20 pfu/ml of the virus, approximately thirty days after the onset of ZIKV symptoms [31].

2.2.2. Sexual transmission

Patients with ZIKV infection have shown evidence of Zika virus RNA in their semen. The virus can spread between the sexes, but male-to-female transmission has the highest transmission frequency [32]. Ratio of viral transmission from male to female: male to male: female to male was 30:1:1 [33].


2.2.3. Vertical transmission

During pregnancy, there is vertical transmission has been observed. ZIKV can be passed from women to their fetuses, as evidenced by the virus's isolation about 4 days later, from the baby brain, amniotic fluid, and baby serum [34].



2.2.4. Blood transfusion

Transfusion of blood Brazil has documented incidences of ZIKV transmission [35], which exacerbates the viruses spread because the majority of ZIKV-infected individuals exhibit no symptoms [36]. Blood recipients can easily contract ZIKV from asymptomatic blood donors. Approximately 3% of blood donors tested positive for the virus. The claim that ZIKV can retain in the blood of an infected individual for almost 60 days exacerbates the situation even more [31]. Developing control methods against ZIKV is a challenging task due to its various mechanisms of transmission.



3. Figure 2: Transmission of ZIKV



There is little information about ZIKV's pathology. It was discovered that human keratin, primitive immune cells, and skin cells were favorable routes for the Zika virus infection [37]. The entry of ZIKV is allowed by the DCSIGN, AXL, Tyro, and TIM-1 invasion/adhesion factors [38]. IF-1 is produced by cells that are contaminated upon ZIKV reproduction, which also triggers a protective defense [39]. Dermal cell infection was found to stimulate the development of therapeutic antigen clusters that can detect a range of molecular features related to the virus. The creation of autophagosomes is linked to increased viral reproduction. ZIKV infection generated an autophagous program, which was verified by the fibroblasts infected with the virus exhibiting distinctive autophagosome-like vesicles [40]. Zika fever induces Th1, Th2, Th9, and Th17 T cell activation during its acute phase [41].

5.2. Replicative Cycle:

Zika virus enter through the host receptors by their glycosylated regions which are present on the envelope protein of virus [42]. Clathrin-coated vesicles are responsible to engulf viral partical into the cell. The virus envelope protein exhibits structural alterations in the endosome's low pH environment, which enabling the virus to fuse with the endosome and release its positive strand RNA [43]. In the reticulum, positive strand of ssRNA is converted into functional polyprotein by translation. Polyprotein is further broken down by the proteases enzymes of host or by viral NS3 and NS2B (non-structural proteins). For instance, to produce negative sense RNA strand, helicase (NS3) and RNA dependent RNA polymerase enzymes also use positive RNA strand as a template [44]. A new positive sense RNA strand can be synthesized by using the negative sense RNA strand as a template. Whether translation or additional application for viral genome replication can be done with the freshly created positive sense RNA strand [45]. When structural proteins are assembled around the viral genome, the particles are transported to the Golgi apparatus, where they cleave the precursor membrane protein to become mature virion and leave the host cell [46]. (Figure 3)




Figure 3: Replication cycle of ZIKV

4. Clinical Manifestations

Only around 20% of infected people have symptoms or indicators of ZIKV infection; mostly patients not show sign and symptoms [47]. Common symptoms include sudden lower level fever with rashes, arthralgia of tiny joints, and non-purulent conjunctivitis [48]. These signs are comparable to the signs of DENV and chikungunya viral disease. Headache, myalgia, asthenia, peripheral edema, and gastrointestinal disruption (abdominal discomfort, nausea, diarrhea) are some other symptoms. After being bitten by an *Aedes* mosquito, symptoms and indicators usually appear two to twelve days later and go away in two to seven days [49]. Patients who have traveled to regions where ZIKV is endemic in the past and exhibit clinical signs and symptoms should be suspected of having the virus. Infants and children with postnatal ZIKV infection exhibit symptoms and indicators that are comparable to those of adults [50]. Infants (and even young children) with arthritis typically exhibit irritability, limping, movement difficulty, and pain when the affected joint is moved, either actively or passively, or when the joint is palpated [50].



5. Diagnosis:

ZIKV infection can be diagnosed by assays for molecular and serological detection the presence of the virus's vector in the area and clinical signs. By using newborn Swiss albino mice, the zika virus was isolated from mosquito samples using variety of techniques, including subcutaneous, intraperitoneal and intracerebral injections [51]. Zika virus was found in brain material passages and this was further verified by the heamagglutination inhibition test [52]. Zika virus can be grown in cell lines such as vero cells, kidney cells from rhesus monkey such as LLC-192 MK2 and mosquito derived cell lines such as *A. albopictus* (C6/36) and *A. pseudoscutellaris* (MOS61 or AP-61) [53].

ZIKV has been determined by compliment fixation test, serum neutralization assay, and heamagglutination inhibition (HI) assay. Antibodies against IgG and IgM are detected as part of the serological diagnosis. IgM antibodies can be examined by using Enzyme Linked Immunosorbant Assay (ELISA) in order to identify antibodies against Zika virus in patient serum. If the titer of the Zika virus neutralizing antibody is greater than four times that of the Dengue neutralizing antibody, the test is regarded as positive otherwise, it is regarded as inconclusive [54]. Due to the irrelevant reaction with other flavivirus members restricts the application of ELISA techniques, the Zika virus induced antibodies can be identified using the Plaque Reduction Neutralization Test (PRNT). PRNT facilitates the differentiation of cross neutralizing antibodies produced by different flaviviruses [55]. Analyzing IgM and IgG titers in paired samples from the acute and convalescent phases of infection confirms seroconversion [56].

Pregnant mothers may undergo ultrasound screening to check for microcephaly [57]. Around five months of pregnancy, a number of fetal abnormalities can be detected; however microcephaly is only detectable around six to seven months gestation or after birth [58]. Molecular and serological tests can be used for additional verification. RT-PCR is used in molecular diagnosis to identify Zika virus RNA [59]. Viral nucleic acids are detectable in the serum during the first seven days of illness. Samples include amniotic fluid, CSF, urine, frozen and fixed placenta, saliva, and nasopharyngeal swab, serum from patients and umbilical cord samples from new-borns [54].



It is necessary to understand the virus shedding in various bodily fluids such as urine which lasts for 15-20 days, in order to develop a more accurate diagnostic tests that uses the right sample [60]. According to a report, viruria may appear more than 15 days after symptoms first appear [61]. Scientist have begun examining antibodies against the Zika virus in amniotic fluid and neonatal blood in order to determine the connection between the virus and microcephaly [62]. DNA sequencing after RT-PCR is considered as confirming [63]. Additional sequencing of the NS5, NS3 and envelope genes verifies the relationship between the different Zika virus strains. It is possible to use real time PCR to find the virus early in the infection process [64]. Additional, it can be verified through the use of immunohistochemistry staining of antigen that has been fixed on the placenta and umbilical cord of infants who are infected [54].

6. Complications:

Numerous problems, including congenital microcephaly, Guillain-Barre syndrome, and even fetus death in pregnant women infected with ZIKV, have been linked to the virus [65].

6.1. Congenital infection:

Zika virus infection in expectant mothers can happen at any stage of the pregnancy and has been linked to microcephaly in the child. Numerous verified reports from Brazil have demonstrated this link, primarily in cases where the infection occurs in the first trimester. Children born after the start of the ZIKV pandemic in Brazil who had microcephaly have also been shown to have cases of muscle atrophy [66]. Pregnancy-related ZIKV infection is linked to several unfavorable consequences for the fetus, including damage to the central nervous system (CNS), placental damage, in-vitro fetal growth inhibition (with or without microcephaly), and even fetal death [67].

6.2. Neurological complications:

A small number of cases linking ZIKV infection to Guillain-Barre disease has been documented [68]. Six days or less before experiencing neurological symptoms, 90% of the patients reported having ZIKV infection symptoms. There have been cases of meningoencephalitis and acute myelitis linked to ZIKV detection in the CSF, among other neurological symptoms [68]. Additionally, reports of ZIKV infection in Italian travelers have included ankle edema, axillary, lymphadenopathy, leukopenia linked with monocytosis, and thrombocytopenia [69].



Treatment:

People infected with ZIKV infection should drink plenty of water, take enough rest, and use liquid solutions to treat fever and pain. If symptoms become severe then go for counselling and therapeutic strategies. Not treatment or prevention of ZIKA virus is present until now, only the medications related to symptomatic relief are present to treat fever and pain like paracetamol [70]. If patient is already taking drugs, then avoid use of any additional medication like Nonsteroidal anti-inflammatory drugs (NSAIDs) [71]. Homeopathy is an important treatment in ZIKV infection as it shown to be effective in encephalitis virus (same genus as of ZIKA virus) treatment in Japanese [70]. Eupatorium is a natural homeopathic compound that can be used as prophylactic treatment against ZIKV infection as it has shown effective for treating symptoms of ZIKV infection [72]. Atropa belladonna, Eupatorium perfoliatum, and Rhustox are homeopathic medicinal treatment against symptoms of ZIKV infection [73]. To reduce mortality and morbidity rate during epidemics of ZIKV infection, homeopathic pharmaceuticals are more effective than conventional methods [74]. Tinospora cordifolia is a green herbal that is immunomodulator that is use for treating viral infection of any nature. These increase the immune system capacity and increase the macrophages' phagocytic activity [75]. These are effective against intestinal diseases, urinary track infections, dengue and other viral infections so, they might be effective against ZIKV infection [70]. In 2016, WHO listed the public based commercial, governmental, and academic projects for making ZIKV interventions so, its treatment and vaccine development is in progress [76]. Since April, 2019 no vaccine for ZIKV infection approved by FDA, is available in market [77]. Production of vaccines for ZIKV is challenging, due to its ZIKV outbreaks had waned, and vaccines should also be safe for pregnant women and avoid neurological effects in adults [78]. There is also lake of funding for vaccines development. Suramin, chloroquine, nitazoxanide are anti-protozoal drugs; avermectin, niclosamide are anthelmintics; sofosbuvir (effective for hepatitis C virus, has shown promising results in treating ZIKV infection transmission from pregnant mice to fetus (especially sofosbuvir) [79]. **(Table 1)**



Table 1: Antiviral drugs against ZIKV and their mode of action

Drugs	Mode of Action
Isoquercitrin, Curcumin, Gossypol, Conessine, Digitonin, Dictyota menstrualis (F6 fraction), Naringenin, Polydatin, Doratoxylem apetalum.	Inhibit ZIKV internalization.
Delphinidin, Berberine, Dictyota menstrualis (Fac-2 fraction), EGCG, Emodin, Palmatine, Harringtonine.	Virucidal activity.
Schinus terebinthifolia (ethanolic fruits' peel extract or whole fruit extract), Digitonin, Naringenin, Conessine, Cinnamic acid.	Inhibits ZIKV replication.
Docosahexaenoic acid (DHA).	Mitochondrial damage and ROS generation.

1. Prevention:

Since there is currently no vaccine against ZIKV on the market, it is essential to develop coordinated, broad, and comprehensive strategies to handle any situation that may arise [80]. Similar to other flavivirus infections. Get lots of rest to manage this infection. Consume liquids to stay hydrated. To lower fever and pain, take medication such as acetaminophen [81]. As Zika-carrying mosquitoes as well as other viruses bite both during the day and at night. So, keep yourself



away from mosquito bites to defeat ZIKV. Everyone should take precautions against mosquito bites, including mothers who are pregnant or breastfeeding. Apply insect repellents with one of the following active chemicals that are registered with the Environmental Protection Agency (EPA). EPA-registered insect repellents are safe and effective when used as prescribed, even for breastfeeding and expectant mothers [82]. On a child's hands, eyes, mouth, cuts, or irritated skin, never use insect repellent. When applying insect repellent to a child's face, adults should first apply it to their hands [83]. Apply sunscreen first and insect repellent second if you're wearing sunscreen. Look both inside and outside for containers that carry water [84]. Restricting the transmission of ZIKAV can be significantly assisted by genetic interference from bacteria such as Wolbachia. A cycling pool of vectors will experience a series of events when Wolbachia bacteria are introduced because the number of mosquitoes carrying the bacteria will grow with each cycle of reproduction [85]. Furthermore, since genetically engineered mosquito strains are successful against DENV, they may also be utilized against ZIKV [86]. The genetically modified (GM) strain *A. aegypti* OX513A has caused a decrease in the *Aegypti* population in the area. Because the GM male mosquitoes can mate with wild-type females, they can eradicate them [87]. Pregnant women should refrain from making unnecessary trips to ZIKV-affected areas to prevent the transmission of the virus to the fetus. The government also has to notify anyone who is planning to visit the areas that have been affected [87]. A person who has Zika can transmit the virus to their partners through intercourse. Sharing of sex toys and oral, anal, and vaginal sex are all considered forms of sex. Even in committed relationships, Zika can be transmitted through intercourse [88]. The Zika virus can remain in semen longer than in other bodily fluids [89], therefore the periods during which men and women can spread the infection through intercourse vary. It is possible to stop the sexual transmission of ZIKV by avoiding unprotected intercourse, sexual contact with infected individuals, and travel from locations where the virus is common [90]. Travelers who return from Zika-affected locations are prohibited from donating blood for 28 days following their return, or until the danger of infection has diminished [91].



2. Ethical implications and concerns of ZIKV infection:

Developing a thorough strategy to manage this public health emergency may require addressing moral dilemmas and ethical concerns about the Zika virus [92]. It is therefore morally necessary for the health authorities to commit to allocating a reasonable amount of health resources for reacting to this scenario [93]. To stop the Zika virus from spreading, the government should prioritize allocating a sizable sum of money for preventive measures [94]. Setting priorities is typically the most challenging stage in these situations, particularly given the lack of sufficient scientific data to estimate the true cost of disease and the influence of the media and society, which was heightened by the 2016 Brazilian Olympic Games [95].

National and international health authorities should uphold the principle of honesty through the implementation of an unambiguous and transparent information-gathering system aimed at increasing public understanding of the actual circumstances [96]. In light of this widespread pattern of disease transmission, "cosmopolitan solidarity" on a global scale appears to be unavoidable [97]. Similar to the Ebola crisis, governments must establish a global health governance network by being responsive to the demands of accountable international organizations, particularly the World Health Organization [98]. When it comes to controlling mosquito populations, governments should strive to limit the spread and reproduction of these insects while also keeping in mind their moral responsibility to maintain biosafety and safeguard ecosystems [99].

To safeguard fundamental civil and human rights, such as the freedom of mobilization and the right to procreate if birth control or a border are among the alternatives, deliberate ethical evaluation is necessary when developing policies for disease control [100]. Similarly, when rules for reporting likely instances to health authorities are discussed, they must respect the confidentiality of patient's health information and shield individuals from stigma [101].

Abortion is at the forefront of moral issues due to the increased risk of congenital abnormalities, primarily microcephaly, in neonates born by moms infected with the Zika virus during their first trimester of pregnancy [102]. Based on the moral standing that different schools of ethics accord the fetus at each stage of development, their stances on abortion range from outright bans to full



moral justifications. As a result, depending on the social, political, religious, and cultural context, abortion regulations continue to vary between nations [103].

In Iran, the "Therapeutic Abortion Act" of 2005 permits abortions only in the presence of a "definite diagnosis of retardation or malformation of the fetus that is unbearable for the mother." This allows abortions to occur no later than 4 months (19th week) after conception, after which time it is illegal and even criminal to attempt an abortion [104].

Conclusion

Zika virus is a significant international threat that demands urgent global. Achieving success requires ongoing comprehensive research to develop an effective vaccine that can effectively combat the virus. It is essential to investigate the interrelationship, action mechanisms, and transmission routes of DENV, ZIKV infection, and chickengunya. Developing a breakthrough in any of these mentioned viruses would be a notable milestone in the medical field, given their genetic similarities within the Flaviviridae family. Until a breakthrough is achieved, a detailed and multifaceted strategy should be utilized to enhance public awareness and manage ZIKV spread by preventing transmission through sexual contact, travel to affected regions and international commerce.

References:

- [1]. Miller MR. *Assessment of Mosquito and Animal Model Factors in Aedes-Borne Arbovirus Transmission and Disease* (Doctoral dissertation, Colorado State University).
- [2]. Mayanja MN, Mwiine FN, Lutwama JJ, Ssekagiri A, Egesa M, Thomson EC, Kohl A. Mosquito-borne arboviruses in Uganda: history, transmission and burden. *Journal of General Virology*. 2021 Jun 24; 102(6):001615.
- [3]. Liu ZY, Shi WF, Qin CF. The evolution of Zika virus from Asia to the Americas. *Nature Reviews Microbiology*. 2019 Mar; 17(3):131-9.
- [4]. Braack L, Gouveia de Almeida AP, Cornel AJ, Swanepoel R, De Jager C. Mosquito-borne arboviruses of African origin: review of key viruses and vectors. *Parasites & vectors*. 2018 Dec; 11:1-26.
- [5]. Faria NR, Azevedo RD, Kraemer MU, Souza R, Cunha MS, Hill SC, Thézé J, Bonsall MB, Bowden TA, Rissanen I, Rocco IM. Zika virus in the Americas: early epidemiological and genetic findings. *Science*. 2016 Apr 15; 352(6283):345-9.
- [6]. Noisumdaeng P, Dangasgul W, Sangsiriwut K, Prasertsopon J, Changsom D, Yoksan S, Ajawatanawong P, Puthavathana P. Molecular characterization and geographical distribution of Zika virus worldwide from 1947 to 2022. *International Journal of Infectious Diseases*. 2023 Nov 1; 136:5-10.



- [7]. Howard CR, Fletcher NF. Emerging virus diseases: can we ever expect the unexpected?. *Emerging microbes & infections*. 2012 Jul 1; 1(1):1-9.
- [8]. Hamel R, Dejarnac O, Wichit S, Ekchariyawat P, Neyret A, Luplertlop N, Perera-Lecoin M, Surasombatpattana P, Talignani L, Thomas F, Cao-Lormeau VM. Biology of Zika virus infection in human skin cells. *Journal of virology*. 2015 Sep 1; 89(17):8880-96.
- [9]. Desforges M, Le Coupanec A, Stodola JK, Meessen-Pinard M, Talbot PJ. Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis. *Virus research*. 2014 Dec 19; 194:145-58.
- [10]. Ribeiro GS, Kitron U. Zika virus pandemic: a human and public health crisis. *Revista da Sociedade Brasileira de Medicina Tropical*. 2016; 49(1):1-3.
- [11]. Kazmi SS, Ali W, Bibi N, Neuron F. A review on Zika virus outbreak, epidemiology, transmission and infection dynamics. *Journal of Biological Research-Thessaloniki*. 2020 Dec; 27:1-1.
- [12]. Pielnaa P, Al-Saadawe M, Saro A, Dama MF, Zhou M, Huang Y, Huang J, Xia Z. Zika virus-spread, epidemiology, genome, transmission cycle, clinical manifestation, associated challenges, vaccine and antiviral drug development. *Virology*. 2020 Apr 1; 543:34-42.
- [13]. Carlson CJ, Dougherty ER, Getz W. An ecological assessment of the pandemic threat of Zika virus. *PLoS Neglected Tropical Diseases*. 2016 Aug 26; 10(8):e0004968.
- [14]. Imperato PJ. The convergence of a virus, mosquitoes, and human travel in globalizing the Zika epidemic. *Journal of community health*. 2016 Jun; 41:674-9.
- [15]. Adebayo G, Neumark Y, Gesser-Edelsburg A, Ahmad WA, Levine H. Zika pandemic online trends, incidence and health risk communication: a time trend study. *BMJ global health*. 2017 Aug 1; 2(3):e000296.
- [16]. De Paula Freitas B, Ventura CV, Maia M, Belfort Jr R. Zika virus and the eye. *Current opinion in ophthalmology*. 2017 Nov 1; 28(6):595-9.
- [17]. Dick GW, Kitchen SF, Haddow AJ. Zika virus (II). Pathogenicity and physical properties.
- [18]. Salehuddin AR, Haslan H, Mamikutty N, Zaidun NH, Azmi MF, Senin MM, Fuad SB, Thent ZC. Zika virus infection and its emerging trends in Southeast Asia. *Asian Pacific journal of tropical medicine*. 2017 Mar 1; 10(3):211-9.
- [19]. Plourde AR, Bloch EM. A literature review of Zika virus. *Emerging infectious diseases*. 2016 Jul; 22(7):1185.
- [20]. Basu R, Tumban E. Zika virus on a spreading spree: what we now know that was unknown in the 1950's. *Virology journal*. 2016 Dec; 13:1-9.
- [21]. Seok S, Raz CD, Miller JH, Malcolm AN, Eason MD, Romero-Weaver AL, Giordano BV, Jacobsen CM, Wang X, Akbari OS, Raban R. Arboviral disease outbreaks, Aedes mosquitoes, and vector control efforts in the Pacific. *Frontiers in Tropical Diseases*. 2023 Jan 25; 4:1035273.



- [22]. Scaramozzino N, Crance JM, Jouan A, DeBriel DA, Stoll F, Garin D. Comparison of flavivirus universal primer pairs and development of a rapid, highly sensitive heminested reverse transcription-PCR assay for detection of flaviviruses targeted to a conserved region of the NS5 gene sequences. *Journal of Clinical Microbiology*. 2001 May 1; 39(5):1922-7.
- [23]. Bos S, Viranaicken W, Turpin J, El-Kalamouni C, Roche M, Krejbich-Trotot P, Desprès P, Gadea G. The structural proteins of epidemic and historical strains of Zika virus differ in their ability to initiate viral infection in human host cells. *Virology*. 2018 Mar 1; 516:265-73.
- [24]. Charrel R, Mögling R, Pas S, Papa A, Baronti C, Koopmans M, Zeller H, Leparç-Goffart I, Reusken CB. Variable sensitivity in molecular detection of Zika virus in European expert laboratories: external quality assessment, November 2016. *Journal of clinical microbiology*. 2017 Nov; 55(11):3219-26.
- [25]. Epelboin Y, Talaga S, Epelboin L, Dusfour I. Zika virus: An updated review of competent or naturally infected mosquitoes. *PLoS neglected tropical diseases*. 2017 Nov 16; 11(11):e0005933.
- [26]. Das B, Ghosal S, Mohanty S. Aedes: What do we know about them and what can they transmit. *Vectors and vector-borne zoonotic diseases*. 2018 Nov 5.
- [27]. Main BJ, Nicholson J, Winokur OC, Steiner C, Riemersma KK, Stuart J, Takeshita R, Krasnec M, Barker CM, Coffey LL. Vector competence of *Aedes aegypti*, *Culex tarsalis*, and *Culex quinquefasciatus* from California for Zika virus. *PLoS neglected tropical diseases*. 2018 Jun 21; 12(6):e0006524.
- [28]. Carter TE, Gebresilassie A, Hansel S, Damodaran L, Montgomery C, Bonnell V, Lopez K, Janies D, Yared S. Analysis of the knockdown resistance locus (kdr) in *Anopheles stephensi*, *An. arabiensis*, and *Culex pipiens* sl for insight into the evolution of target-site pyrethroid resistance in eastern Ethiopia. *The American journal of tropical medicine and hygiene*. 2022 Feb; 106(2):632.
- [29]. Du S, Liu Y, Liu J, Zhao J, Champagne C, Tong L, Zhang R, Zhang F, Qin CF, Ma P, Chen CH. *Aedes* mosquitoes acquire and transmit Zika virus by breeding in contaminated aquatic environments. *Nature communications*. 2019 Mar 22; 10(1):1324.
- [30]. Bonaldo MC, Ribeiro IP, Lima NS, Dos Santos AA, Menezes LS, da Cruz SO, de Mello IS, Furtado ND, de Moura EE, Damasceno L, da Silva KA. Isolation of infective Zika virus from urine and saliva of patients in Brazil. *PLoS neglected tropical diseases*. 2016 Jun 24; 10(6):e0004816.
- [31]. Lustig Y, Mendelson E, Paran N, Melamed S, Schwartz E. Detection of Zika virus RNA in whole blood of imported Zika virus disease cases up to 2 months after symptom onset, Israel, December 2015 to April 2016. *Eurosurveillance*. 2016 Jun 30; 21(26):30269.
- [32]. Deckard DT. Male-to-male sexual transmission of Zika virus—Texas, January 2016. *MMWR. Morbidity and mortality weekly report*. 2016; 65.



- [33]. Foy BD, Kobylinski KC, Foy JL, Blitvich BJ, da Rosa AT, Haddock AD, Lanciotti RS, Tesh RB. Probable non-vector-borne transmission of Zika virus, Colorado, USA. *Emerging infectious diseases*. 2011 May; 17(5):880.
- [34]. Krauer F, Riesen M, Reveiz L, Oladapo OT, Martínez-Vega R, Porgo TV, Haeffliger A, Broutet NJ, Low N, WHO Zika Causality Working Group. Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barré syndrome: systematic review. *PLoS medicine*. 2017 Jan 3; 14(1):e1002203.
- [35]. Magnus MM, Espósito DL, Costa VA, Melo PS, Costa-Lima C, Fonseca BA, Addas-Carvalho M. Risk of Zika virus transmission by blood donations in Brazil. *Hematology, transfusion and cell therapy*. 2018; 40(3):250-4.
- [36]. Musso D, Nhan T, Robin E, Roche C, Bierlaire D, Zisou K, Yan AS, Cao-Lormeau VM, Broult J. Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. *Eurosurveillance*. 2014 Apr 10; 19(14):20761.
- [37]. El Costa H, Gouilly J, Mansuy JM, Chen Q, Levy C, Cartron G, Veas F, Al-Daccak R, Izopet J, Jabrane-Ferrat N. ZIKA virus reveals broad tissue and cell tropism during the first trimester of pregnancy. *Scientific reports*. 2016 Oct 19; 6(1):35296.
- [38]. Agrelli A, de Moura RR, Crovella S, Brandão LA. ZIKA virus entry mechanisms in human cells. *Infection, Genetics and Evolution*. 2019 Apr 1; 69:22-9.
- [39]. Wang J, Jiang B, Wang K, Dai J, Dong C, Wang Y, Zhang P, Li M, Xu W, Wei L. A cathelicidin antimicrobial peptide from *Hydrophis cyanocinctus* inhibits Zika virus infection by downregulating expression of a viral entry factor. *Journal of Biological Chemistry*. 2022 Oct 1; 298(10).
- [40]. Musso D, Gubler DJ. Zika virus. *Clinical microbiology reviews*. 2016 Jul; 29(3):487-524.
- [41]. Castillo-Macías A, Salinas-Carmona MC, Torres-López E. Immunology of viral infections with a high impact in Mexico: Dengue, Chikungunya, and Zika. *Medicina Universitaria*. 2017 Oct 1; 19(77):198-207.
- [42]. Routhu NK, Lehoux SD, Rouse EA, Bidokhti MR, Giron LB, Anzurez A, Reid SP, Abdel-Mohsen M, Cummings RD, Byrareddy SN. Glycosylation of Zika virus is important in host-virus interaction and pathogenic potential. *International journal of molecular sciences*. 2019 Oct 21; 20(20):5206.
- [43]. Wang B, Thurmond S, Hai R, Song J. Structure and function of Zika virus NS5 protein: perspectives for drug design. *Cellular and molecular life sciences*. 2018 May; 75:1723-36.
- [44]. Šebera J, Dubankova A, Sychrovský V, Ruzek D, Boura E, Nencka R. The structural model of Zika virus RNA-dependent RNA polymerase in complex with RNA for rational design of novel nucleotide inhibitors. *Scientific reports*. 2018 Jul 24; 8(1):11132.
- [45]. Sager G, Gabaglio S, Sztul E, Belov GA. Role of host cell secretory machinery in Zika virus life cycle. *Viruses*. 2018 Oct 15; 10(10):559.



- [46]. Heinz FX, Stiasny K. The antigenic structure of Zika virus and its relation to other flaviviruses: implications for infection and immunoprophylaxis. *Microbiology and Molecular Biology Reviews*. 2017 Mar; 81(1):10-128.
- [47]. Yadav S, Rawal G, Baxi M. Zika virus: a pandemic in progress. *Journal of translational internal medicine*. 2016 Apr 1; 4(1):42-5.
- [48]. Marano G, Pupella S, Vaglio S, Liumbruno GM, Grazzini G. Zika virus and the never-ending story of emerging pathogens and transfusion medicine. *Blood transfusion*. 2016 Mar; 14(2):95.
- [49]. Basarab M, Bowman C, Aarons EJ, Cropley I. Zika virus. *Bmj*. 2016 Feb 26; 352.
- [50]. Fleming-Dutra KE. Update: interim guidelines for health care providers caring for infants and children with possible Zika virus infection—United States, February 2016. *MMWR. Morbidity and mortality weekly report*. 2016; 65.
- [51]. Marchette NJ, Garcia R, Rudnick A. Isolation of Zika virus from *Aedes aegypti* mosquitoes in Malaysia.
- [52]. Haddow AJ, Williams MC, Woodall JP, Simpson DI, Goma LK. Twelve isolations of Zika virus from *Aedes (Stegomyia) africanus* (Theobald) taken in and above a Uganda forest. *Bulletin of the World Health Organization*. 1964; 31(1):57.
- [53]. Waggoner JJ, Pinsky BA. Zika virus: diagnostics for an emerging pandemic threat. *Journal of clinical microbiology*. 2016 Apr; 54(4):860-7.
- [54]. Staples JE. Interim guidelines for the evaluation and testing of infants with possible congenital Zika virus infection—United States, 2016. *MMWR. Morbidity and mortality weekly report*. 2016; 65.
- [55]. Lessler J, Chaisson LH, Kucirka LM, Bi Q, Grantz K, Salje H, Carcelen AC, Ott CT, Sheffield JS, Ferguson NM, Cummings DA. Assessing the global threat from Zika virus. *Science*. 2016 Aug 12; 353(6300):aaf8160.
- [56]. Pyke AT, Daly MT, Cameron JN, Moore PR, Taylor CT, Hewitson GR, Humphreys JL, Gair R. Imported Zika virus infection from the Cook Islands into Australia, 2014. *PLoS currents*. 2014 Jun 2; 6.
- [57]. Melo AO, Malinger G, Ximenes R, Szejnfeld PO, Sampaio SA, De Filippis AB. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg? *Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology*. 2016 Jan; 47(1):6-7.
- [58]. Lazear HM, Stringer EM, de Silva AM. The emerging Zika virus epidemic in the Americas: research priorities. *Jama*. 2016 May 10; 315(18):1945-6.
- [59]. Shukla S, Hong SY, Chung SH, Kim M. Rapid detection strategies for the global threat of Zika virus: current state, new hypotheses, and limitations. *Frontiers in microbiology*. 2016 Oct 24; 7:1685.
- [60]. Moulin E, Selby K, Cherpillod P, Kaiser L, Boillat-Blanco N. Simultaneous outbreaks of dengue, chikungunya and Zika virus infections: diagnosis challenge in a returning traveller with nonspecific febrile illness. *New microbes and new infections*. 2016 May 1; 11:6-7.



- [61]. Rozé B, Najioullah F, Fergé JL, Apetse K, Brouste Y, Cesaire R, Fagour C, Fagour L, Hochedez P, Jeannin S, Joux J. Zika virus detection in urine from patients with Guillain-Barre syndrome on Martinique, January 2016. *Eurosurveillance*. 2016 Mar 3; 21(9):30154.
- [62]. Jacob JA. Researchers focus on solving the Zika riddles. *JAMA*. 2016 Mar 15; 315(11):1097-9.
- [63]. Zanoluca C, Melo VC, Mosimann AL, Santos GI, Santos CN, Luz K. First report of autochthonous transmission of Zika virus in Brazil. *Memórias do Instituto Oswaldo Cruz*. 2015 Jun 9; 110(4):569-72.
- [64]. Tognarelli J, Ulloa S, Villagra E, Lagos J, Aguayo C, Fasce R, Parra B, Mora J, Becerra N, Lagos N, Vera L. A report on the outbreak of Zika virus on Easter Island, South Pacific, 2014. *Archives of virology*. 2016 Mar; 161(3):665-8.
- [65]. Melo AO, Malinger G, Ximenes R, Szejnfeld PO, Sampaio SA, De Filippis AB. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg?. *Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology*. 2016 Jan; 47(1):6-7.
- [66]. Ventura CV, Maia M, Bravo-Filho V, Góis AL, Belfort R. Zika virus in Brazil and macular atrophy in a child with microcephaly. *The Lancet*. 2016 Jan 16; 387(10015):228.
- [67]. Mayor S. Zika infection in pregnancy is linked to range of fetal abnormalities, data indicate. *BMJ: British Medical Journal (Online)*. 2016 Mar 7; 352.
- [68]. Oehler E, Watrin L, Larre P, Leparc-Goffart I, Lastere S, Valour F, Baudouin L, Mallet HP, Musso D, Ghawche F. Zika virus infection complicated by Guillain-Barre syndrome—case report, French Polynesia, December 2013. *Eurosurveillance*. 2014 Mar 6; 19(9):20720.
- [69]. Mécharles S, Herrmann C, Poullain P, Tran TH, Deschamps N, Mathon G, Landais A, Breurec S, Lannuzel A. Acute myelitis due to Zika virus infection. *The Lancet*. 2016 Apr 2; 387(10026):1481.
- [70]. Saxena SK, Elahi A, Gadugu S, Prasad AK. Zika virus outbreak: an overview of the experimental therapeutics and treatment. *VirusDisease*. 2016 Jun; 27:111-5.
- [71]. 22. RISK R. Microcephaly in Brazil potentially linked to the Zika virus epidemic.
- [72]. Calvet G, Aguiar RS, Melo AS, Sampaio SA, de Filippis I, Fabri A, Araujo ES, de Sequeira PC, de Mendonça MC, de Oliveira L, Tschoeke DA. Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: a case study. *The Lancet infectious diseases*. 2016 Jun 1; 16(6):653-60.
- [73]. Bousta D, Soulimani R, Jarmouni I, Belon P, Falla J, Froment N, Younos C. Neurotropic, immunological and gastric effects of low doses of *Atropa belladonna* L., *Gelsemium sempervirens* L. and *Poumon histamine* in stressed mice. *Journal of Ethnopharmacology*. 2001 Mar 1; 74(3):205-15.
- [74]. Ullman D. Controlled clinical trials evaluating the homeopathic treatment of people with human immunodeficiency virus or acquired immune deficiency syndrome. *The Journal of Alternative & Complementary Medicine*. 2003 Feb 1; 9(1):133-41.



- [75]. Mittal J, Sharma MM, Batra A. *Tinospora cordifolia*: a multipurpose medicinal plant-A. *Journal of Medicinal Plants*. 2014; 2(2).
- [76]. Quanquin N, Wang L, Cheng G. Potential for treatment and a Zika virus vaccine. *Current opinion in pediatrics*. 2017 Feb 1; 29(1):114-21.
- [77]. Abbink P, Stephenson KE, Barouch DH. Zika virus vaccines. *Nature Reviews Microbiology*. 2018 Oct; 16(10):594-600.
- [78]. Pattnaik A, Sahoo BR, Pattnaik AK. Current status of Zika virus vaccines: successes and challenges. *Vaccines*. 2020 May 31; 8(2):266.
- [79]. Gardinali NR, Marchevsky RS, Oliveira JM, Pelajo-Machado M, Kugelmeier T, Castro MP, Silva AC, Pinto DP, Fonseca LB, Vilhena LS, Pereira HM. Sofosbuvir shows a protective effect against vertical transmission of Zika virus and the associated congenital syndrome in rhesus monkeys. *Antiviral Research*. 2020 Oct 1; 182:104859.
- [80]. World Health Organization. Zika strategic response plan, revised for July 2016-December 2017. World Health Organization; 2016.
- [81]. Drwiega EN, Danziger LH, Burgos RM, Michienzi SM. Commonly reported mosquito-borne viruses in the United States: a primer for pharmacists. *Journal of Pharmacy Practice*. 2024 Jun; 37(3):741-52.
- [82]. Fradin MS. Insect protection. In *Travel medicine 2019* Jan 1 (pp. 43-52). Elsevier.
- [83]. Tavares M, Da Silva MR, De Siqueira LB, Rodrigues RA, Bodjolle-d'Almeida L, Dos Santos EP, Ricci-Júnior E. Trends in insect repellent formulations: A review. *International journal of pharmaceutics*. 2018 Mar 25; 539(1-2):190-209.
- [84]. Sharma A, Lal SK. Zika virus: transmission, detection, control, and prevention. *Frontiers in microbiology*. 2017 Feb 3; 8:110.
- [85]. Verma M, Phartyal R, Bhatt A. Introduction to Flaviviruses and Their Global Prevalence. In *Human Viruses: Diseases, Treatments and Vaccines: The New Insights 2021* May 20 (pp. 411-439). Cham: Springer International Publishing.
- [86]. Singh RK, Dhama K, Khandia R, Munjal A, Karthik K, Tiwari R, Chakraborty S, Malik YS, Bueno-Marí R. Prevention and control strategies to counter Zika virus, a special focus on intervention approaches against vector mosquitoes—current updates. *Frontiers in microbiology*. 2018 Feb 8; 9:87.
- [87]. Qsim M, Ashfaq UA, Yousaf MZ, Masoud MS, Rasul I, Noor N, Hussain A. Genetically modified *Aedes aegypti* to control dengue: a review. *Critical Reviews™ in Eukaryotic Gene Expression*. 2017; 27(4).
- [88]. Oster AM. Interim guidelines for prevention of sexual transmission of Zika virus—United States, 2016. *MMWR. Morbidity and mortality weekly report*. 2016; 65.



- [89]. Joguet G, Mansuy JM, Matusali G, Hamdi S, Walschaerts M, Pavili L, Guyomard S, Prisant N, Lamarre P, Dejuq-Rainsford N, Pasquier C. Effect of acute Zika virus infection on sperm and virus clearance in body fluids: a prospective observational study. *The Lancet Infectious Diseases*. 2017 Nov 1; 17(11):1200-8.
- [90]. World Health Organization. WHO guidelines for the prevention of sexual transmission of Zika virus. World Health Organization; 2018 Nov 7.
- [91]. Amorim L. Zika Virus. *Blood Safety: A Guide to Monitoring and Responding to Potential New Threats*. 2019:163-86.
- [92]. Saenz C. Zika virus: ethics preparedness for old and new challenges. *The Lancet Global health*. 2016 Oct 1; 4(10):e686.
- [93]. Barnett DJ, Taylor HA, Hodge Jr JG, Links JM. Resource allocation on the frontlines of public health preparedness and response: report of a summit on legal and ethical issues. *Public Health Reports*. 2009 Mar; 124(2):295-303.
- [94]. Alfaro-Murillo JA, Parpia AS, Fitzpatrick MC, Tamagnan JA, Medlock J, Ndeffo-Mbah ML, Fish D, Ávila-Agüero ML, Marín R, Ko AI, Galvani AP. A cost-effectiveness tool for informing policies on Zika virus control. *PLoS neglected tropical diseases*. 2016 May 20; 10(5):e0004743.
- [95]. Baker DE. Zika virus and the media. *Hospital pharmacy*. 2016 Apr; 51(4):275-6.
- [96]. Guttman N, Salmon CT. Guilt, fear, stigma and knowledge gaps: ethical issues in public health communication interventions. *Bioethics*. 2004 Nov; 18(6):531-52.
- [97]. Lencucha R. Cosmopolitanism and foreign policy for health: ethics for and beyond the state. *BMC international health and human rights*. 2013 Dec; 13:1-1.
- [98]. Kickbusch I, Reddy KS. Global health governance—the next political revolution. *Public health*. 2015 Jul 1; 129(7):838-42.
- [99]. Macer D. Ethical, legal and social issues of genetically modifying insect vectors for public health. *Insect biochemistry and molecular biology*. 2005 Jul 1; 35(7):649-60.
- [100]. Bueno MA, Grunspun H. Bioethical considerations at times of Zika virus. *Einstein (Sao Paulo)*. 2016; 14(2):13-8.
- [101]. Klingler C, Silva DS, Schuermann C, Reis AA, Saxena A, Streh D. Ethical issues in public health surveillance: a systematic qualitative review. *BMC public health*. 2017 Dec; 17:1-3.
- [102]. I Hassan F, Niaz K, Maqbool F, Khan F, Abdollahi M. Congenital abnormalities: consequence of maternal Zika virus infection: a narrative review. *Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders)*. 2017 Mar 1; 17(1):3-13.
- [103]. Shapiro GK. Abortion law in Muslim-majority countries: an overview of the Islamic discourse with policy implications. *Health policy and planning*. 2014 Jul 1; 29(4):483-94.
- [104]. Abbasi M, Gooshki ES, Allahbedashti N. Abortion in Iranian legal system. *Iranian Journal of Allergy, Asthma and Immunology*. 2014:71-84.